abstract |
The present invention relates to anti-CD19 antibodies with variant Fc regions with some specific amino acid modifications relative to the wild type Fc region conferring one or several useful effector functions. In particular, the invention relates to chimeric, humanized or fully human anti-CD19 antibodies comprising the variant Fc region. It advantageously relates to antibodies having interesting and valuable glycosylation features, especially low fucose levels and/or high oligomannose levels and low levels of sialylated glycoforms. The invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially B-cell malignancies, and auto-immune diseases. |